Literature DB >> 1985048

Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics.

A Hadengue1, M K Benhayoun, D Lebrec, J P Benhamou.   

Abstract

The prevalence of pulmonary hypertension in 507 patients hospitalized with portal hypertension but without known pulmonary hypertension who underwent cardiac catheterization was prospectively studied. Ten (2%) of these patients, 6 of whom were clinically asymptomatic, had primary pulmonary hypertension. Second, 26 patients with symptomatic pulmonary hypertension complicating portal hypertension were reviewed. Pulmonary hypertension occurred later after diagnosis of portal hypertension in patients with a surgical shunt (10 patients) than in those without a shunt (147 +/- 49 vs. 44 +/- 27 months; P less than 0.0001). Cardiac index correlated inversely with pulmonary arterial pressure (r = -0.45; P less than 0.01) and was lower in the 5 patients who died of pulmonary hypertension than in the 5 who died of liver failure (1.52 +/- 0.14 vs. 3.69 +/- 1.88 L/min.m2; P less than 0.05). Third, systemic and splanchnic hemodynamics were compared in 285 patients with alcoholic cirrhosis and 29 controls. No significant relation was found between elevated pulmonary vascular resistance and increased portal pressure, zzygos blood flow, or cardiac index. Pulmonary hypertension is considerably more frequent than was previously estimated in patients with portal hypertension. The risk of developing pulmonary hypertension could increase with the duration of portal hypertension without any clear relation to the degree of portal hypertension, hepatic failure, or amount of blood shunted.

Entities:  

Mesh:

Year:  1991        PMID: 1985048     DOI: 10.1016/0016-5085(91)90225-a

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  69 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

2.  Esophageal variceal ligation for esophageal variceal hemorrhage in a patient with portal and primary pulmonary hypertension complicating myelofibrosis.

Authors:  W C Lee; H C Lin; S H Tsay; Y Y Yang; M C Hou; F Y Lee; F Y Chang; S D Lee
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

Review 3.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

4.  Portopulmonary hypertension: challenges in diagnosis and management.

Authors:  Patrick J Troy; Aaron B Waxman
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

5.  Portopulmonary hypertension in pediatric patients.

Authors:  Adria A Condino; D Dunbar Ivy; Judith A O'Connor; Michael R Narkewicz; Sarah Mengshol; John R Whitworth; Lori Claussen; Aimee Doran; Ronald J Sokol
Journal:  J Pediatr       Date:  2005-07       Impact factor: 4.406

Review 6.  The extrahepatic consequences of cirrhosis.

Authors:  Jin Kee Ho; Eric Yoshida
Journal:  MedGenMed       Date:  2006-03-02

Review 7.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

Review 8.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

9.  Development of hypoxemia in alcoholic liver disease.

Authors:  Shigeo Maruyama; Chisato Hirayama; Kazunori Maeda; Satoru Yamamoto; Masaharu Koda; Akihide Udagawa; Masayuki Inoue; Kensuke Umeki
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

10.  Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension: a case report.

Authors:  E M Yoshida; S R Erb; D N Ostrow; D R Ricci; C H Scudamore; G Fradet
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.